New treatments for ulcerative colitis: do we have pediatric data?

The ECCO/ESPGHAN guidelines extensively reviewed how to employ the existing therapies for active pediatric ulcerative colitis (UC), including helpful algorithms for guiding treatment decisions [1,2]. These guidelines center on initial use of mesalasine, before using steroids, thiopurines and anti-TNF for more severe or refractory cases. As many as 20% of children will require colectomy within childhood/early adult life [3,4]. In this review we aim to discuss new approaches for using existing therapies and discuss data on emerging therapies, both of which are likely to lead to improved disease outcome in pediatric UC.

[1]  K. Kolho,et al.  Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial , 2016, Journal of Crohn's & colitis.

[2]  A. Goyal,et al.  P-214 A Study of Fecal Microbiota Transplantation in Pediatric Patients with Inflammatory Bowel Disease , 2016 .

[3]  V. Annese,et al.  Review article: the natural history of paediatric‐onset ulcerative colitis in population‐based studies , 2016, Alimentary pharmacology & therapeutics.

[4]  J. Kierkuś,et al.  Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. , 2016, Journal of Crohn's & colitis.

[5]  A. Griffiths,et al.  Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network , 2016, Journal of pediatric gastroenterology and nutrition.

[6]  M. Elawad,et al.  Short article: Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis , 2015, European journal of gastroenterology & hepatology.

[7]  N. Loman,et al.  Extensive Modulation of the Fecal Metagenome in Children With Crohn's Disease During Exclusive Enteral Nutrition , 2015, The American Journal of Gastroenterology.

[8]  E. Zoetendal,et al.  Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.

[9]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[10]  M. Dubinsky,et al.  321 Vedolizumab Use in Pediatric Patients With Inflammatory Bowel Disease , 2015 .

[11]  Namita Singh,et al.  Fecal Microbial Transplant Via Nasogastric Tube for Active Pediatric Ulcerative Colitis , 2015, Journal of pediatric gastroenterology and nutrition.

[12]  J. Versalovic,et al.  Tu1192 Clinical, Epigenetic, and Metagenomic Responses to Serial Fecal Microbiome Transplants in Pediatric Ulcerative Colitis , 2014 .

[13]  D. Schwartz,et al.  Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis–Predominant IBD , 2014, Journal of pediatric gastroenterology and nutrition.

[14]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[15]  S. Kugathasan,et al.  Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis , 2013, Journal of pediatric gastroenterology and nutrition.

[16]  David C. Wilson,et al.  Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines , 2012, Journal of pediatric gastroenterology and nutrition.

[17]  B. Feagan,et al.  Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[18]  A. Griffiths,et al.  Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  R. Russell,et al.  Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine , 2011, Alimentary pharmacology & therapeutics.

[20]  David C. Wilson,et al.  Consensus for Managing Acute Severe Ulcerative Colitis in Children: A Systematic Review and Joint Statement From ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN , 2011, The American Journal of Gastroenterology.

[21]  Bill Pikounis,et al.  Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α , 2010, mAbs.

[22]  David C Wilson,et al.  Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. , 2008, Gastroenterology.

[23]  K. Kolho,et al.  Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. , 2016, Journal of Crohn's & colitis.

[24]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[25]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.